BiotechTube

[203Pb]VMT01 + [68Ga]VMT02

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Melanoma (Skin)

Conditions

Melanoma (Skin), Melanoma Stage IV, Melanoma, Uveal, Melanoma, Mucosal

Trial Timeline

Mar 5, 2021 → Sep 20, 2022

NCT ID
NCT04904120

About [203Pb]VMT01 + [68Ga]VMT02

[203Pb]VMT01 + [68Ga]VMT02 is a phase 1 stage product being developed by Perspective Therapeutics for Melanoma (Skin). The current trial status is completed. This product is registered under clinical trial identifier NCT04904120. Target conditions include Melanoma (Skin), Melanoma Stage IV, Melanoma, Uveal.

What happened to similar drugs?

4 of 20 similar drugs in Melanoma (Skin) were approved

Approved (4) Terminated (2) Active (14)
✅dabrafenib + trametinibNovartisApproved
✅ZelborafRocheApproved
✅Nivolumab + RelatlimabBristol Myers SquibbApproved
✅Fibrin Sealant (Tisseel) used in the Experimental Arm.BaxterApproved
❌Tasisulam-sodium + PaclitaxelEli LillyPhase 3
🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04904120Phase 1Completed

Competing Products

20 competing products in Melanoma (Skin)

See all competitors
ProductCompanyStageHype Score
mRNA-4157 + PembrolizumabMerckPhase 2
39
AVT32-DRL_PB + KeytrudaDr. Reddy's LaboratoriesPhase 1
33
Binimetinib Oral TabletBiotrialPhase 1
15
Tasisulam-sodium + PaclitaxelEli LillyPhase 3
32
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
FYB206 + KeytrudaFormycon AGPhase 1
23
PLX3397Daiichi SankyoPre-clinical
26
PLX3397 + PembrolizumabDaiichi SankyoPhase 1/2
24
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
DS-8273a + NivolumabDaiichi SankyoPhase 1
29
PLX3397 + vemurafenibDaiichi SankyoPhase 1
21
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
42
CP-461Astellas PharmaPhase 2
27
YM155Astellas PharmaPhase 2
35
YM155 + DocetaxelAstellas PharmaPhase 2
35
Denileukin diftitoxEisaiPhase 2
35
E7080EisaiPhase 1
29
lenvatinib + pembrolizumabEisaiPhase 2
35
MORAb-004 (monoclonal antibody)EisaiPhase 2
35
Pembrolizumab + LenvatinibEisaiPhase 2
39